CMP
MRK icon

Coston McIsaac & Partners’s Merck MRK Stock Holding History

Coston McIsaac & Partners’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.03M Sell
8,604
-817
-9% -$94.3K 0.23% 62
2025
Q4 		$991K Sell
9,421
-438
-4% -$41.1K 0.23% 67
2025
Q3 		$827K Buy
9,859
+43
+0.4% +$3.54K 0.2% 73
2025
Q2 		$777K Sell
9,816
-670
-6% -$53.3K 0.2% 76
2025
Q1 		$941K Buy
10,486
+207
+2% +$19.3K 0.27% 61
2024
Q4 		$1.02M Buy
10,279
+5
+0% +$515 0.3% 57
2024
Q3 		$1.17K Buy
10,274
+4
+0% +$475 0.33% 51
2024
Q2 		$1.27M Buy
10,270
+3
+0% +$386 0.4% 46
2024
Q1 		$1.35M Buy
10,267
+4
+0% +$493 0.43% 45
2023
Q4 		$1.12M Buy
10,263
+35
+0.3% +$3.63K 0.39% 48
2023
Q3 		$1.05M Sell
10,228
-86
-0.8% -$9.27K 0.4% 48
2023
Q2 		$1.19M Buy
10,314
+94
+0.9% +$10.7K 0.41% 53
2023
Q1 		$1.09M Buy
10,220
+124
+1% +$13.4K 0.4% 54
2022
Q4 		$1.12K Sell
10,096
-128
-1% -$13.1K 0.44% 52
2022
Q3 		$880K Buy
10,224
+5
+0% +$446 0.4% 51
2022
Q2 		$932K Buy
+10,219
New +$906K 0.56% 44

Other funds holding MRK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Coston McIsaac & Partners's MRK Position: Q1 2026 in Review

Coston McIsaac & Partners reduced its Merck (MRK) stake by 8.7% in Q1 2026, selling an estimated $94.3K and leaving 8,604 shares worth $1.03M. The position accounts for 0.23% of the portfolio, ranked #62.

Coston McIsaac & Partners first reported a position in MRK in Q2 2022 and has held it in 16 quarters since. The position peaked at $1.35M in Q1 2024. 3,780 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Coston McIsaac & Partners held 8,604 shares of Merck worth $1.03M as of Q1 2026.
  • Coston McIsaac & Partners sold 817 Merck shares in Q1 2026, an estimated $94.3K.
  • Merck made up 0.23% of Coston McIsaac & Partners's portfolio in Q1 2026, its #62 holding.
  • Coston McIsaac & Partners first reported a position in Merck in Q2 2022 and has held it in 16 quarters since.
  • Coston McIsaac & Partners's Merck position peaked at $1.35M in Q1 2024.
  • 3,780 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Coston McIsaac & Partners's 13F filing for Q1 2026, filed 22 Apr 2026.